Innovent Says Takeda Wins Japan SAKIGAKE Designation for Gastric Cancer Drug Arcotatug Tavatecan

By Public Technologies
  • Innovent Biologics announced Nov. 17, 2026, that Takeda received Japan's SAKIGAKE designation for arcotatug tavatecan (IBI343/TAK-921).
  • The proposed indication covers CLDN18.2-positive unresectable advanced or recurrent gastric or gastroesophageal junction adenocarcinoma progressing after chemotherapy.
  • The designation provides eligibility for priority regulatory consultation and priority review in Japan.
  • The supporting Phase 3 G-HOPE-001 trial demonstrated meaningful survival benefits, delayed disease progression and a superior safety profile.
  • Results from the trial, conducted in China and Japan, were already presented at the 2026 European Society for Medical Oncology Congress.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.